West Virginia AG: ‘Woefully Deficient’ Mylan Settlement Sends ‘Message Of Leniency’
West Virginia Attorney General Patrick Morrisey sent a letter to U.S. Attorney General Loretta Lynch blasting the $465 million settlement, which came about over charges that Mylan improperly classified the EpiPen allergy auto-injector in reports to the Medicaid Drug Rebate Program.
Stat:
West Virginia AG Vows To Reject 'Woefully Deficient' Mylan Deal With The Feds
In blunt language, West Virginia Attorney General Patrick Morrisey is vowing to reject the settlement between the federal government and Mylan Pharmaceuticals, which was accused of shortchanging Medicaid. In a letter to US Attorney General Loretta Lynch, he called the $465 million “woefully deficient” compared with the “fraud” perpetrated by the drug maker and urged the Department of Justice not to follow through with the deal. (Silverman, 11/2)
Reuters:
West Virginia Urges Justice Dept To Reject Settlement With Mylan
West Virginia Attorney General Patrick Morrisey on Wednesday blasted Mylan NV's announced $465 million settlement with the U.S. Justice Department over the drugmaker's classification of its lifesaving allergy treatment EpiPen as a generic, saying the amount was "woefully deficient." The department has not acknowledged such a deal almost a month after Mylan announced it, and department spokeswoman Nicole Navas declined to comment on Wednesday. (Lynch, 11/2)
Morning Consult:
W.Va. Attorney General Slams Proposed Mylan Settlement
A settlement announced by Mylan Pharmaceuticals under which it would pay $465 million without admitting wrongdoing for overcharging Medicaid for EpiPens isn’t strong enough and should be rejected, West Virginia Attorney General Patrick Morrisey says. Morrisey wrote in a Wednesday letter to the Department of Justice that the settlement, which was announced by Mylan last month but has not been confirmed by the department, would be a “windfall” for the drug company. (McIntire, 11/2)
The Star Tribune:
Senators Ask Mylan To Provide Detailed EpiPen Pricing Info
A group of 17 U.S. senators, including Minnesotans Amy Klobuchar and Al Franken, have raised new questions about Mylan Pharmaceuticals’ profit margins on its EpiPen epinephrine auto-injector. In a Nov. 1 letter to Mylan CEO Heather Bresch, the senators called for the company to provide detailed breakdowns on pricing of the product for the uninsured, Medicare and Medicaid recipients, people with employer-provided health insurance and those insured individually as part of the Affordable Care Act. (Spencer, 11/2)
